HIGHLIGHTS
- who: Viraj R. Sanghvi and colleagues from the Department of Molecular and Cellular Pharmacology, Sylvester Comprehensive Center, Miller School of Medicine, University of Miami, Miami, FL, USA have published the article: NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy, in the Journal: Cancers 2021, 639. of 29/01/2021
- what: The authors examine the effect of a synthetic eIF4A inhibitor (CR-1-31 B) against aggressive, MYC and BCL2 positive lymphomas and the authors specifically explore potential mechanisms of resistance to the eIF4A inhibitor treatment.
- how: For immunoblotting the authors used . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.